BIOMAT Database Logo BIOMAT Database Logo

Histological changes of the liver by treatment of chronic non-A, non-B hepatitis with recombinant leukocyte interferon alpha. Comparison with histological changes in chronic hepatitis B. 1989

M Omata, and Y Ito, and O Yokosuka, and F Imazeki, and K Uchiumi, and S Takano, and K Hosoda, and M Ohto
First Department of Medicine, Chiba University School of Medicine, Japan.

We have treated 17 patients with non-A, non-B chronic hepatitis by recombinant interferon alpha (0.3-9 megaunits for 4-28 weeks). In six patients, serum aminotransferase levels fell to normal or near-normal range during treatment. The mean levels of serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in 17 patients fell from 156 +/- 80 (mean +/- SD) and 213 +/- 135 at the beginning of treatment to 94 +/- 49 and 112 +/- 71, respectively, at the end of treatment. In 12 patients, liver biopsies were performed before and after (or during) the treatment, and histological activity indices (HAI) were blindly examined by two independent observers. For comparison, we examined histological changes of pre- and posttreatment liver biopsies of 19 patients who were treated by recombinant interferon for chronic hepatitis B. Mean HAI scores improved from 10.0 to 5.4 after treatment in non-A, non-B chronic hepatitis. The most marked reduction was noted in scores of portal inflammation and hepatocellular degeneration and/or necrosis. No such reduction was observed in B-viral chronic hepatitis. These data indicated that rapid biochemical resolution by the treatment was related to histological improvement of the liver in our patients with non-A, non-B hepatitis.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D005260 Female Females
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006525 Hepatitis, Viral, Human INFLAMMATION of the LIVER in humans due to infection by VIRUSES. There are several significant types of human viral hepatitis with infection caused by enteric-transmission (HEPATITIS A; HEPATITIS E) or blood transfusion (HEPATITIS B; HEPATITIS C; and HEPATITIS D). Viral Hepatitis, Human,Human Viral Hepatitides,Human Viral Hepatitis,Viral Hepatitides, Human
D006526 Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted,Parenterally-Transmitted Non-A, Non-B Hepatitis,PT-NANBH,Parenterally Transmitted Non A, Non B Hepatitis

Related Publications

M Omata, and Y Ito, and O Yokosuka, and F Imazeki, and K Uchiumi, and S Takano, and K Hosoda, and M Ohto
Recombinant leukocyte interferon treatment of chronic hepatitis B.
January 1985, Hepatology (Baltimore, Md.),
M Omata, and Y Ito, and O Yokosuka, and F Imazeki, and K Uchiumi, and S Takano, and K Hosoda, and M Ohto
Therapy of chronic non-A, non-B hepatitis with alpha interferon. A comparison between natural and recombinant alpha interferon.
December 1993, La Clinica terapeutica,
M Omata, and Y Ito, and O Yokosuka, and F Imazeki, and K Uchiumi, and S Takano, and K Hosoda, and M Ohto
Treatment of chronic hepatitis B with recombinant leukocyte interferon and cyanidanol.
February 1988, Gastroenterologia Japonica,
M Omata, and Y Ito, and O Yokosuka, and F Imazeki, and K Uchiumi, and S Takano, and K Hosoda, and M Ohto
Treatment of chronic hepatitis B with recombinant interferon alpha versus recombinant interferon alpha plus levamisole.
November 1993, Journal of hepatology,
M Omata, and Y Ito, and O Yokosuka, and F Imazeki, and K Uchiumi, and S Takano, and K Hosoda, and M Ohto
Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report.
December 1986, The New England journal of medicine,
M Omata, and Y Ito, and O Yokosuka, and F Imazeki, and K Uchiumi, and S Takano, and K Hosoda, and M Ohto
Modification of hepatitis B virus infection by recombinant leukocyte alpha A interferon.
September 1986, Immunobiology,
M Omata, and Y Ito, and O Yokosuka, and F Imazeki, and K Uchiumi, and S Takano, and K Hosoda, and M Ohto
Recombinant alpha 2-interferon treatment in children with chronic hepatitis B.
January 1988, Lancet (London, England),
M Omata, and Y Ito, and O Yokosuka, and F Imazeki, and K Uchiumi, and S Takano, and K Hosoda, and M Ohto
Recombinant alpha 2-interferon treatment in children with chronic hepatitis B.
April 1988, Lancet (London, England),
M Omata, and Y Ito, and O Yokosuka, and F Imazeki, and K Uchiumi, and S Takano, and K Hosoda, and M Ohto
Interferon-alpha 2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: a quantitative histological evaluation.
December 1993, Hepatology (Baltimore, Md.),
M Omata, and Y Ito, and O Yokosuka, and F Imazeki, and K Uchiumi, and S Takano, and K Hosoda, and M Ohto
Histological outcome in interferon alpha-2b treated patients with chronic posttransfusion non-A, non-B hepatitis.
February 1991, Liver,
Copied contents to your clipboard!